Print This Post

Etravirine (Intelence) Approved for HIV Treatment

The Food and Drug Administration (FDA) has approved a new HIV drug recommended as an adjunct therapy for patients who did not respond to other treatment regimens. Etravirine (Intelence) belongs to a new class of anti-HIV drugs known as non-nucleoside reverse transcriptase inhibitors (NNRTI).

Findings of two clinical trials showed that a combination of darunavir (Prezista) and etravirine (Intelence) was associated with higher percentage of patients reaching undetectable levels of HIV, than a single darunavir (Prezista) therapy. A total of 599 individuals participated in these randomized, double-blind, placebo-controlled trials.

The FDA points out that the long-term effects of etravirine therapy are not known and that the safety and effectiveness in children and individuals under 16 years of age, has not been tested. Most common side effects of etravirine include nausea and rash. It is strongly recommended that those individuals who develop rash, contact their doctor as soon as possible.

• OTC Pediatric Cold Remedies Not Safe, Not Effective For Kids Under 4
• NYC Subways Join the Battle of the Bulge
• Crohn’s Patients Gain Quality of Life with New Treatment Plan
• Consumer Reports Rates Nutrition Value of Kids’ Cereals
• Sex Triggers Stroke for Woman, 35
• FTC Says Bogus Cancer Cures Just More Snake Oil
• Easy Ways to Make Kids’ Breakfasts Nutritious, Delicious